Screening for multiple myeloma

A groundbreaking approach to identify monoclonal proteins

For patients at risk of plasma cell disorders, early identification is critical to ensure better outcomes. Coined as MASS-FIX, our innovative approach uses matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and marks the first major breakthrough in multiple myeloma screening since gel electrophoresis was developed in 1967.

Now included in International Myeloma Working Group recommendations

  • MASS-FIX is now included in International Myeloma Working Group recommendations as an accepted method for screening of M-proteins.

By weighing M-proteins, this method overcomes electrophoresis’s limitations in detection and provides the most accurate understanding of a patient’s M-proteins. This novel testing also helps health care providers understand their patients’ risk of progression to multiple myeloma or AL amyloidosis. This level of insight is not possible via traditional testing methods.

Key testing

DMOGA | Monoclonal Gammopathy, Diagnostic, Serum

Analytic time: 2 days  

Appropriate ordering scenario 

  • Assessing the risk of progression from MGUS to multiple myeloma 

PEISO | Protein Electrophoresis and Isotype, Serum

Analytic time: 2 days  

Appropriate ordering scenario 

  • Diagnosis of monoclonal gammopathies, when used in conjunction with serum free light-chain studies performed at client site 

Enhanced test panel for monoclonal gammopathy: Finding the fingerprint

Like a thief in the night, multiple myeloma sneaks up on people. The incurable blood cancer almost always starts as a relatively benign condition — monoclonal gammopathy of undetermined significance, or MGUS — that has no symptoms and often goes undiagnosed.

Learn more about how to order these evaluations at your institution.

Additional resources

Monoclonal gammopathy informative cases

Mayo Clinic Laboratories provides evaluation and consultation for the diagnosis and treatment of patients with hereditary and acquired hematologic disorders. View these cases for examples of when the test should be ordered.

A Test in Focus: Screening and monitoring of monoclonal gammopathies

David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests. Our testing is validated and developed through the use of in-house clinical studies. We also reference publications and research in each of our reports to provide clinical evidence to our interpretations.